Comparer des méthodes

	Questionnaire sur la maladie inflammatoire de l'intestin	EORTC QLQ-C30
Domaine	Résultats de santé	Résultats de santé
Famille	Process / pipeline	Process / pipeline
Année d'origine	1994	1993
Auteur d'origine	Elena J. Irvine et al.	Nico Aaronson et al.
Type	Self-report quality of life questionnaire	Self-report quality of life questionnaire
Source fondatrice	Guyonnet, S., Dupont, C., Mouterde, O., Chouraqui, J. P., Darmaun, D., & Goulet, O. (2001). Placebo-controlled trial of saccharomyces boulardii in gastroenteritis. Pediatrics, 107(2), E27.	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
Alias	IBDQ, IBD Questionnaire, Inflammatory Bowel Disease QoL	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale
Apparentées	4	5
Résumé	The IBDQ is a disease-specific quality of life measure for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Developed by Elena Irvine and colleagues in 1994, this 32-item questionnaire measures how IBD affects bowel function, systemic symptoms, emotional well-being, and social functioning. It is the most widely used quality-of-life instrument in IBD research and clinical practice.	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.